Rinaploem Controlled Release Tablets 12.5/2.5/1000 mg (Empagliflozin, Linagliptin, Metformin Hydrochloride)
Empagliflozin 12.5mg · Linagliptin Micronized 2.5mg +1 more
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
MFDS item code 202502781 · Approved 2025.10.28
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise to improve blood sugar control in patients with type 2 diabetes. It contains a combination of three ingredients: empagliflozin, linagliptin, and metformin, which work together to assist in blood sugar management and effectively maintain stable blood sugar levels. Therefore, this medication is used to enhance blood sugar control in patients with type 2 diabetes.
For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum daily dose of each component: empagliflozin 25mg, linagliptin 5mg, and extended-release metformin hydrochloride 2000mg. This drug should be taken once daily in the evening with a meal to reduce gastrointestinal adverse reactions caused by metformin hydrochloride. If adjustment of the metformin hydrochloride dose is necessary, the dose should be adjusted gradually. Patients taking this drug as 10/5/1000mg or 25/5/1000mg extended-release tablets should take 1 tablet once daily. Patients taking this drug as 5/2.5/1000mg or 12.5/2.5/1000mg extended-release tablets should take 2 tablets once daily. For patients who tolerate the recommended starting dose of this drug, empagliflozin 10mg/linagliptin 5mg/metformin hydrochloride 1000mg once daily, but need additional glycemic control, the dose of empagliflozin or metformin may be increased. Patients switching from concomitant therapy with empagliflozin, linagliptin, and metformin hydrochloride to this drug should receive the same doses they were taking previously. The safety and efficacy of this drug have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because this may cause changes in glycemic control, any change in treatment for patients with type 2 diabetes should be made under careful monitoring. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. To maintain its extended-release properties, this drug must be swallowed whole and must not be split, crushed, ground, or chewed. This drug may not dissolve completely and may be excreted in the stool. It is not known whether the substance excreted in the stool contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Special Populations Patients with Renal Impairment The efficacy and safety of this drug vary according to renal function, and dose adjustment based on renal function is necessary. Therefore, assessment of renal function before starting this drug and periodically during treatment is recommended. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this drug may be used by adjusting the dose of metformin hydrochloride, one of its components, provided it is well tolerated and the patient does not have other conditions that may increase the risk of lactic acidosis. The starting dose of extended-release metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, this drug should be discontinued immediately. Renal function should be assessed every 3~6 months.
This medication can cause a rare side effect known as severe lactic acidosis, which may threaten life; therefore, caution is required. The risk of lactic acidosis is particularly high in patients with significantly impaired kidney function or those with heart, liver, or lung dysfunction. Therefore, this medication should not be used in patients with severely impaired kidney function, those undergoing dialysis, patients with acute metabolic acidosis, or patients with severe heart failure. Additionally, patients who are about to undergo surgery, or those with severe infections, dehydration, or excessive alcohol intake should temporarily pause the use of this medication. There may be an increased risk of hypoglycemia if this drug is used in combination with other medications that lower blood sugar; if taking insulin or sulfonylureas alongside this medication, dose adjustments may be necessary. During treatment with this medication, regular blood tests should be conducted to monitor kidney function and vitamin B12 levels, and any abnormal symptoms should be promptly reported to the medical staff. Furthermore, this medication may increase the risk of urinary tract infections or genital fungal infections; if related symptoms occur, prompt treatment should be sought. Elderly patients or those at risk of reduced fluid volume should be cautious about dehydration and hypotension, and should consult a physician if any symptoms arise. This medication should be swallowed whole and not chewed or crushed; in some patients, the tablet coating may be excreted in stool, which is not a cause for concern. Caution is necessary when driving or operating machinery due to the risk of hypoglycemia, especially when combined with other blood sugar-lowering agents. It is advisable to avoid alcohol consumption during treatment, as acute or chronic excessive alcohol intake may increase the risk of lactic acidosis. Lastly, there may be interactions with other medications used in conjunction with this one, so it is essential to inform healthcare providers of all medications being taken.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it should be stored in a sealed container. To maintain the efficacy of the medication, it is recommended to store it at room temperature, between 1 degree Celsius and 30 degrees Celsius.
White and light blue, oval, film-coated tablets with a double convex surface.
Bottle packaging - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 12.5mg · Linagliptin Micronized 2.5mg +1 more
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
Empagliflozin 10mg · Linagliptin Micronized 5mg +1 more
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
Empagliflozin 5mg · Linagliptin Micronized 2.5mg +1 more
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
Empagliflozin 25mg · Linagliptin Micronized 5mg +1 more
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.